ONCOSTELLAE Revenue and Competitors

ONCOSTELLAE Discovery and development of novel small-molecule drugs in (immune) oncology and inflammatory/autoimmune diseases Drug discovery company. Generation of high impact programs, mainly in immunology and oncology. Discovery and optimization of NCEs for validated targets, including preclinical development and Phase I/IIa. Exit through licensing agreements with consolidated pharma companies. All developments have evolved from internal medicinal chemistry programs and are based on proprietary NCEs (composition of matter, priority filings in 2017). DEVELOPMENT PIPELINE >OST-122: Oral, gut-restricted Jak3/Tyk2-Ark5 inhibitor (IBD) in POC study in ulcerative colitis patients >OST-499: Oral, non-steroidal GR/PR antagonist (Enza/Abi-resistant PC, I/O) in pharmaceutical development for FIH Ph1 clinical trial. LICENSING OPPORTUNITY: We are actively seeking to close a partnering agreement for our gut-restricted and subtype-selective Jak3/Tyk2 inhibitor OST-122. After achieving some important clinical objectives in the recently completed Phase 1 trial, such as excellent safety and tolerability at all doses, maximum GI restriction / minimal systemic exposure and high compound levels in feces, we push forward with the preparations of a POC study in Ulcerative Colitis patients for which we have secured financing and identified clinical collaborators / hospital centers in Spain. Study start Q2 2020. Based on these achievements and on the good prospects for locally acting JAK inhibitors in IBD (and other indications), we have started partnering discussions already at this stage and are open to various modalities including licensing/option/local agreements. The concept of designing organ-selective and therefore safer JAK inhibitors is being explored in other programs directed at the local treatment of inflammatory/autoimmune diseases of the lung, skin and eye.